ImmunoPulse™ IL-12


To date, OncoSec’s immunotherapy platform, ImmunoPulse™, focuses on the delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The treatment is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, which in turn, enables the immune system to target and attack tumors throughout the body.

OncoSec is currently investigating ImmunoPulse™ IL-12 for treatment of metastatic melanoma, head and neck cancer, and triple negative breast cancer. As the company continues to evaluate ImmunoPulse™ IL-12 in these current indications, OncoSec is developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

How it Works


Cancer is identified in the body.


DNA-based interleukin-12 (IL-12), a naturally occurring protein, is injected directly into the tumor.


The applicator supplies a sequence of short-duration electrical pulses through a series of needles.


Electrical pulses result in increased permeability of the cell membrane, allowing DNA-based IL-12 to enter.


DNA-based IL-12 is expressed in the local tumor microenvironment.


IL-12 drives local inflammatory response in the tumor.


Immune cells are educated to recognize the patient’s cancer.


Educated immune cells identify and attack tumors throughout the body.

Positive Results

Data from our multi-center Phase II trial of ImmunoPulse™ IL-12 demonstrated encouraging single-agent activity in 29 patients with metastatic melanoma.

Best Overall Response

Complete Response

Disease Control Rate

Patients Showing Complete Regression in at Least One Untreated Lesion